Article: Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers.
Journal of bone oncology
2015 Volume 4, Issue 1, Page(s) 1–12
Abstract: ... controlled by the release of polypeptide mediators activating signalling pathways through several receptor tyrosine kinases ... of bone sarcomas and bone metastases. ... Bone cancers are characterised by the development of tumour cells in bone sites, associated ...
| Abstract | Bone cancers are characterised by the development of tumour cells in bone sites, associated with a dysregulation of their environment. In the last two decades, numerous therapeutic strategies have been developed to target the cancer cells or tumour niche. As the crosstalk between these two entities is tightly controlled by the release of polypeptide mediators activating signalling pathways through several receptor tyrosine kinases (RTKs), RTK inhibitors have been designed. These inhibitors have shown exciting clinical impacts, such as imatinib mesylate, which has become a reference treatment for chronic myeloid leukaemia and gastrointestinal tumours. The present review gives an overview of the main molecular and functional characteristics of RTKs, and focuses on the clinical applications that are envisaged and already assessed for the treatment of bone sarcomas and bone metastases. |
|---|---|
| Language | English |
| Publishing date | 2015-01-23 |
| Publishing country | Netherlands |
| Document type | Journal Article ; Review |
| ISSN | 2212-1366 |
| ISSN | 2212-1366 |
| DOI | 10.1016/j.jbo.2015.01.001 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.
Inter-library loan at ZB MED
Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.